Please login to the form below
CAR-T therapies
This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.
Relics from the past
In oncology, CAR-T therapies involve such complex approaches that they can hardly just be called drugs anymore. ... We may still be calling companies ‘pharma’ when their gene therapies hardly count as pharmaceuticals.
Latest news
-
FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel). ... therapies. The CAR-T therapy targets CD19, a protein which
-
FDA approves Roche’s Actemra COVID-19 trial
It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with ... T cell therapies for cancer.
-
China backs use of Roche’s Actemra for coronavirus
and CRS associated with CAR-T cell therapies for cancer.
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
It’s a similar approach to CAR-T therapy, but according to Immatics TCRs should have broader utility because they can be targeted at proteins inside cancer cells. ... Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’
-
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma
One notable side effect of CAR-T therapies is cytokine release syndrome (CRS) – as CAR T cells multiply, they cause huge amounts of chemicals called cytokines to be released into the ... The uptake of CAR-T therapies, however, has proven difficult, as
More from news
Approximately 3 fully matching, plus 86 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers
-
The impact of COVID-19 on clinical trials
impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged
-
Cortellis Drugs to Watch in 2020 report
Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and
-
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and
-
European biotech: a new generation of leaders emerges
year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of
More from intelligence
Approximately 0 fully matching, plus 26 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
In the precision medicine era, the line between products and services is blurred
Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.
-
Precision paediatrics: Treating patients with CAR-T
It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
-
Highlights in haematologic malignancy from ASH 2018
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
-
Download our infographic: Addressing the biggest challenges for rare disease communities
Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
-
Training the next generation of biotech leaders
In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality, with companies in the
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Account Director
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- UK pharmacies to begin administering COVID-19 vaccinations
- J&J could launch its single-dose COVID-19 vaccine in March
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Future-Proofing Healthcare and Medicine
- AI in Computer Vision Technology and the Impact on Healthcare
- Lateral flow tests detect ‘most infectious’ COVID-19 cases, Oxford researchers find
- Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- BMS aims for US approval of Opdivo combo in stomach cancer
PMHub
Graphite Digital
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...
Latest intelligence
- The pandemic preparedness paradox
- Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Quick links
Infographics
